Skip to main content
. 2012 Mar;27(3):687–693. doi: 10.1002/jbmr.1472

Table 1.

Baseline Characteristics

Placebo (N = 3906) Denosumab (N = 3902)
Age (years), mean ± SD 72.3 ± 5.2 72.3 ± 5.2
Total hip BMD T-score, mean ± SD –1.91 ± 0.81 –1.89 ± 0.81
Lumbar spine BMD T-score, mean ± SD –2.84 ± 0.69 –2.82 ± 0.70
Prevalent vertebral fracture, % (n) 23.4% (915) 23.8% (929)
History of nonvertebral fracture in those ≥55 years, % (n) 30.1% (1177) 29.8% (1163)
History of nonvertebral fracture, % (n) 38.6% (1507) 39.1% (1524)